Quest Diagnostics stock heads into October 22 results with Q2 growth now in view
Quest Diagnostics (DGX) is preparing to release its third-quarter 2026 results on October 22, 2026, building on a strong second quarter where revenue rose 10.2% to $3.04 billion and adjusted EPS hit $3.12, surpassing consensus estimates. Analysts maintain a "Moderate Buy" rating with an average price target of $237.08, slightly above its recent closing price of $233.32. The upcoming report will be crucial for revenue progression, EPS delivery, and any adjustments to the full-year guidance of $11.05 to $11.25 adjusted EPS.
A director defers cash pay for 135 stock-linked units at Quest Diagnostics (DGX).
Quest Diagnostics director Timothy C. Wentworth acquired 135 Phantom Stock Units on October 1, 2026, through an elective deferral of his cash compensation. These units, which become payable in cash upon his termination of service as a director, increase his total holdings to 477 Phantom Stock Units. This transaction is categorized as neutral in filing impact and sentiment, reflecting a routine compensation deferral rather than a direct stock purchase.
Quest Diagnostics Incorporated (DGX) latest press releases and corporate news
This article provides a compilation of recent press releases and corporate news for Quest Diagnostics (DGX). Key announcements include robust clinical performance for Haystack MRD®, the launch of a heart screening program in Florida, and the upcoming release of third-quarter financial results. The company also announced a cash dividend and has been featured in market analyses for NICU genetic testing and clinical laboratory services.
Interested In Quest Diagnostics' (NYSE:DGX) Upcoming US$0.86 Dividend? You Have Three Days Left
Quest Diagnostics (NYSE:DGX) is set to pay a quarterly dividend of US$0.86 per share, with the ex-dividend date in three days on October 6, 2026. The company's dividend is well-covered by both earnings and free cash flow, with payout ratios of 35% and 27% respectively, indicating sustainability. While earnings per share have declined slightly over the past five years, the dividend has grown by 8.5% annually, suggesting a stable dividend despite some concerns about earnings growth.
Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8
Quest Diagnostics (NYSE:DGX) has been identified as a breakout setup candidate due to its strong technical rating of 7 and a setup quality rating of 8, indicating a solid underlying uptrend with a workable entry point. The article details the methodology behind these ratings, highlighting DGX's consistent price appreciation and market outperformance, alongside a defined risk envelope for potential traders. While the short-term trend shows some ambiguity, the combination of strong trend and tight consolidation makes DGX an attractive candidate for a breakout strategy.
Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials
Quest Diagnostics (DGX) announced significant findings regarding the high accuracy of its Haystack MRD test in detecting residual and recurrent disease in colorectal cancer and other solid tumors, as published in The Journal of Molecular Diagnostics. Despite the positive clinical news, GuruFocus' GF Value™ metric indicates that DGX's stock is modestly overvalued, trading above its intrinsic value, and insider activity shows selling rather than buying. The company holds a strong GF Score™ of 77/100, primarily driven by solid profitability and financial strength, though its valuation and momentum are noted as headwinds.
Quest Diagnostics Incorporated (DGX) Latest Stock News & Headlines
This article provides the latest news and headlines for Quest Diagnostics (DGX), including its stock performance and recent announcements. Key updates include a declared cash dividend, clinical performance demonstrations for Haystack MRD®, and a new heart screening program in Florida. The company's stock has seen significant gains year-to-date, despite concerns about potential Medicare payment cuts.
The Galleri MCD vote: What FDA asked its advisors to ignore
This podcast episode discusses the FDA's advisory committee meeting on GRAIL Inc.'s multi-cancer detection test, Galleri. The FDA instructed its advisors to ignore clinical benefit claims and focus solely on the test's ability to detect cancers in asymptomatic individuals, sparking debate about the role of mortality reduction in test approvals and the appropriate nomenclature for "early detection." The episode highlights concerns about public perception, potential over-testing, and the broader implications for cancer screening regulations, particularly regarding the term "early detection."
Quest Diagnostics stock heads toward October 22 results
Quest Diagnostics stock (ISIN US74834L1008) closed at EUR 209.60 on September 29, 2026, slightly down. The company is set to release its Q3 2026 results on October 22, 2026, before the US market opens, following a strong Q2 performance with revenue up 10.2 percent and adjusted EPS up 19.1 percent. Analysts like Truist Financial have raised their price target for Quest Diagnostics, emphasizing the upcoming Q3 report as crucial operating evidence for its valuation.
Quest Diagnostics stock draws a USD 260.00 target after earnings
Truist Financial has raised its price target for Quest Diagnostics (DGX) to USD 260.00 while maintaining a Hold rating, following the company's Q2 2026 adjusted EPS of USD 3.12, which beat consensus estimates. Revenue also exceeded expectations at USD 3.04 billion. The next financial update is scheduled for October 22, 2026, when Quest Diagnostics will release its third-quarter results.
FDA panel endorses first-of-a-kind cancer blood test from Grail
A federal health advisory panel has endorsed Grail Inc.'s Galleri blood test, which is designed to detect signs of various cancers in healthy individuals. The panel voted that the DNA-based test offers more potential benefits than risks for people aged 50 and older, despite concerns about its accuracy in detecting early-stage cancers and the potential for false alarms or false assurances. While the FDA is not bound by the advice, a positive decision could lead to wider adoption and insurance coverage for this first-of-its-kind technology.
Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x Run
Guardant Health (GH) has seen its stock increase fivefold over the past three years, prompting questions about whether its current valuation is supported by future cash flows. The company's recent expansion of coverage for its Shield blood test is expected to boost future cash inflows significantly, with analysts forecasting a move from current cash burning to substantial free cash generation by the early 2030s, which could justify its current share price of $177.25. However, there are differing views, with some narratives suggesting the stock is undervalued by 9% due to AI integration, while others indicate it could be overvalued by 17% due to reimbursement challenges.
Wisconsin Joins $2.3M Labcorp Data Breach Settlement
Wisconsin has joined a 44-state settlement with Labcorp, resolving a 2019 data breach that originated at a third-party debt collector, AMCA, and affected over 27.5 million people nationwide, including 16,615 Wisconsin residents. The settlement requires Labcorp to pay $2.3 million and implement significant reforms to its vendor security and data management practices. This case highlights a growing regulatory focus on holding companies accountable for vendor-related data exposures.
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
Quest Diagnostics (DGX) shares have surged 36.3% year-to-date, outperforming both its industry and the S&P 500, driven by strong momentum in advanced diagnostics. The company is experiencing broad-based growth across physician, hospital, and consumer-testing channels, further boosted by strategic acquisitions and the adoption of AI and automation for efficiency. While high leverage and exposure to reimbursement changes remain concerns, analyst estimates project significant EPS and revenue growth for 2026 and 2027.
FDA panel endorses Grail Galleri multi-cancer blood test
An FDA advisory panel has recommended Grail Inc.'s Galleri multi-cancer blood test, marking the first time such a federal group has endorsed a multi-cancer detection test. The panel unanimously supported the test's safety, split on its effectiveness, and ultimately concluded that its benefits outweigh its risks for adults 50 and older. The FDA's final decision on nationwide commercial availability is expected within months, though the advisory panel's recommendations are not binding.
Quest Diagnostics stock gains 1.48 percent after Truist raises target
Quest Diagnostics (DGX) saw its stock increase by 1.48% to USD 236.44 after Truist Financial raised its price target to USD 260. Baird also increased its target to USD 260. The company reported strong Q2 2026 revenues of USD 3.04 billion, a 10.2% increase year-over-year, and provided a positive full-year 2026 guidance.
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
Quest Diagnostics (DGX) shares have rallied 36.3% year-to-date, outperforming the industry and S&P 500. This growth is attributed to strong momentum in advanced diagnostics, expansion in oncology, broad-based growth across various customer channels, and the adoption of AI and automation for efficiency. The company's future growth is expected to be supported by rising chronic disease rates and increasing demand for early diagnosis, despite concerns about high leverage and exposure to reimbursement changes.
New blood test can detect more than 50 types of cancer. Here’s what to know
Federal health advisers have endorsed Grail Inc.'s Galleri blood test, which can detect signs of over 50 types of cancer in healthy individuals, though they cautioned about its limitations. The advisory panel voted that the test offers potential benefits despite concerns about false positives or negatives, and noted that more research is needed to prove its effectiveness for early detection. If the FDA approves it, widespread U.S. adoption could follow, making it more accessible through insurance coverage, but it should be used in conjunction with, not as a replacement for, existing cancer screenings.
Quest Diagnostics stock heads into the open after a 0.4 percent gain
Quest Diagnostics stock gained 0.4 percent to close at USD 236.10 on September 24, 2026, outperforming the S&P 500. Barclays maintained a Buy rating and a USD 250 price target for the company. US trading is set to resume on September 25, 2026, with the S&P 500 and Nasdaq Composite serving as broad-market references.
BrightSpring Health Services (BTSG) Short Interest & Short Float | Updated Sep 2026
As of September 15, 2026, BrightSpring Health Services (BTSG) had a short interest of 10.18 million shares, representing 5.30% of its public float, which is a 0.36% increase from the prior report. The short interest ratio is 4.6 days to cover, indicating it would take 4.6 days of average trading volume to cover all short positions. The article provides a historical table of short interest data and answers frequently asked questions about BTSG's short interest metrics and comparison to competitors.
Quest Diagnostics stock reports growth as reimbursement risk rises
Quest Diagnostics reported strong Q2 2026 revenue growth of 10.2% to $3.043 billion, and raised its full-year revenue outlook. Despite this growth, the stock experienced a slight decline in after-hours trading due to a narrower operating margin and the impending risk of up to 15% reimbursement cuts from the Centers for Medicare and Medicaid Services in 2027, posing a challenge for investors.
F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test
An FDA advisory committee has recommended approval for Grail's Galleri blood test, designed to detect various cancers early, despite concerns from doctors regarding its efficacy. Although hundreds of thousands have used the test, there's no data from randomized controlled trials showing it reduces cancer deaths, and a large trial in the U.K. failed to show a reduction in advanced cancer diagnoses. The test currently costs $949 out-of-pocket, but successful lobbying could lead to Medicare coverage starting in 2028 if FDA approval is granted.
Inspire Medical Systems, Inc. (INSP) latest stock news and headlines
This article provides the latest news and stock performance data for Inspire Medical Systems, Inc. (INSP). It highlights that the stock closed at $68.81 with a slight decrease and mentions several recent financial news articles and analyst recommendations. The performance overview shows that INSP has had negative trailing total returns year-to-date, 1-year, and 3-year periods, underperforming the S&P 500.
Investigation launched into STAAR Surgical for possible fiduciary breaches affecting shareholders.
Levi & Korsinsky has initiated an investigation into STAAR Surgical Company concerning potential breaches of fiduciary duties, raising concerns about the company's management practices. This probe could lead to legal action or shareholder claims, impacting current investors who can seek further information or legal counsel at no cost. The article also provides a brief market snapshot for the health sector, noting that 78 out of 100 US health-sector stocks fell on September 24, 2026.
FDA panel endorses first-of-a-kind cancer blood test from Grail
A federal health advisory panel has endorsed Grail Inc.'s Galleri blood test for detecting signs of various cancers in healthy individuals, despite acknowledging uncertainties about its effectiveness and the need for further study. The panel voted 7-2 that the benefits outweigh the risks, paving the way for potential widespread adoption if the FDA agrees, though they stressed it should supplement, not replace, existing cancer screenings.
Labcorp Holdings Inc. (LH) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Labcorp Holdings Inc. (LH), including its current stock price, financial statistics, historical data, and recent news. The company, a diagnostics and research healthcare provider, offers various laboratory services and has recently highlighted strategic priorities for growth and shareholder value. The article also includes performance comparisons against the S&P 500 and analyst insights, with Truist Securities maintaining a "Buy" rating and raising the price target to $365.
Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions.
Quest Diagnostics (DGX) demonstrates growth potential due to consistent demand for routine testing and opportunities in dialysis and advanced diagnostics, supported by its acquisition strategy. Despite near-term Medicare uncertainties, analysts view its valuation as a speculative buy. The company is set to release its Q3 2026 earnings on October 22.
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Quest Diagnostics (NYSE: DGX) announced it will release its third-quarter 2026 financial results on October 22, 2026, before market open. The company will also host a conference call on the same day at 8:30 a.m. Eastern Time to discuss the results. Details for accessing the live webcast and call replay are provided for investors and interested parties.
FDA advisory panel recommends a first: multi-cancer blood test
An FDA advisory panel has recommended approval for Grail's Galleri blood test, the first multi-cancer detection blood test, for individuals aged 50 and over. While the test can detect up to 50 forms of cancer, concerns were raised about its effectiveness in early detection and potential for false senses of security. The panel's recommendation includes caveats for marketing materials, emphasizing that the test should supplement, not replace, standard cancer screenings.
Quest Diagnostics stock falls 4.29 percent ahead of the open
Quest Diagnostics stock fell 4.29 percent to USD 234.38 on September 22, 2026, driven by proposed Medicare rate cuts for laboratory services. The shares underperformed the Nasdaq Composite, which saw a slight gain. The company is scheduled to release its third-quarter 2026 financial results on October 22, 2026.
Before markets open, Quest Diagnostics will report results Oct. 22
Quest Diagnostics (NYSE: DGX) announced it will release its third-quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. The company will also host a conference call to discuss the results at 8:30 a.m. Eastern Time. Investors can access the earnings release and webcast via Quest Diagnostics' investor relations website.
Charles River Labs stock rises 2.19 percent ahead of the open
Charles River Labs (ISIN US1591881009, Nasdaq: CRL) stock rose 2.19 percent to USD 285.11 on September 22, 2026, outperforming competitors like Labcorp and Quest Diagnostics. This move occurred alongside a mixed session for US equities, with the S&P 500 slightly down and the Nasdaq Composite reaching a record close. The article reports on the stock's performance ahead of the next US trading session.
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
A Quest Diagnostics study published in JAMA Network Open reveals that nearly one-third of patients with Lyme disease antibodies also show co-exposure to at least one other tick-borne pathogen, particularly in Lyme disease-endemic regions. The study, which analyzed 193,260 individuals, emphasizes the need for comprehensive diagnostic testing due to overlapping symptoms and different treatment requirements for co-infections like babesiosis and anaplasmosis. Quest Diagnostics' stock, DGX, saw a slight dip after the announcement but has significantly outperformed the industry year-to-date, with the findings expected to boost demand for broader tick-borne disease testing.
Labcorp reaffirms long-term outlook despite preliminary CMS payment cuts
Labcorp (LH) has reaffirmed its 2026-2029 long-term outlook, despite preliminary Medicare payment cuts for laboratory services announced by the CMS. The company expects sustained growth in revenue, operating margin, EPS, and free cash flow, having already factored such reimbursement pressures into its guidance. Labcorp also highlighted the negative impact of these cuts on patient access and continues to support the bipartisan RESULTS Act.
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Quest Diagnostics (NYSE: DGX) announced it will release its third-quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results, with access details provided for both live participation and replay. The earnings release and webcast will be available on their investor relations website.
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Quest Diagnostics (NYSE: DGX) will report its third-quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results. The earnings release and a live webcast will be available on the Quest Diagnostics investor relations website.
Labcorp stock falls as CMS proposes 15 percent reimbursement cuts
Labcorp stock fell 5.9 percent in premarket trading after the Centers for Medicare and Medicaid Services (CMS) proposed reimbursement cuts of up to 15 percent for laboratory services. This policy creates a direct earnings risk for Labcorp and other diagnostic-testing companies. Despite this, Truist Securities raised Labcorp's price target, indicating that analysts are balancing regulatory pressure with the company's long-term fundamentals.
Quest Diagnostics stock falls as Medicare cuts threaten 2027 earnings
Quest Diagnostics stock fell after a proposed 15% Medicare fee cut was announced, threatening its 2027 earnings despite strong second-quarter results. The stock reached a 52-week high before the announcement, and analysts have raised price targets based on recent performance, but the potential reimbursement cuts introduce uncertainty. The policy risk now challenges the company's earnings durability, despite a 43% year-to-date gain and a solid market capitalization.
Perspective: First-Void Urine - A New Era in Accessible STI Testing
This article, titled "Perspective: First-Void Urine - A New Era in Accessible STI Testing," highlights the potential of first-void urine as a more accessible and convenient method for STI testing. It suggests that this approach could usher in a new era for improving public health by making testing easier for individuals.
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
A Quest Diagnostics study published in JAMA Network Open revealed that nearly one-third of patients with Lyme disease antibodies also showed antibodies for at least one other tick-borne pathogen, highlighting frequent co-exposure. The findings suggest a need for comprehensive diagnostic testing, especially in Lyme-endemic areas, given the overlapping symptoms and different treatment requirements for co-infections. This study reinforces Quest Diagnostics' role in tick-borne disease diagnosis and aligns with the growing market for Lyme disease testing.
Is Quest Diagnostics Stock Outperforming the Nasdaq?
Quest Diagnostics (DGX) has significantly outperformed the Nasdaq Composite ($NASX) over the past three months, year-to-date, and over the last 52 weeks, driven by growth in core routine testing and advanced diagnostics. The company's strategic acquisitions, partnerships, and consumer-initiated testing have further strengthened its market position. Analysts maintain a "Moderate Buy" rating for DGX, with a modest upside potential from current price levels.
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics (DGX) shows strong growth in physician, hospital, and consumer channels, driven by customer wins, acquisitions, and an expanding advanced diagnostics portfolio. The company is also implementing AI and automation for cost savings. However, it faces challenges from reimbursement uncertainty, cost pressures, and elevated debt levels.
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics is surpassing its growth targets, driven by strong organic growth, increased consumer-health demand, and strategic partnerships. CEO Jim Davis noted that the company's revenue and earnings growth are exceeding previous projections, with significant contributions from its direct-to-consumer operations and health-system collaborations. The company is also navigating potential impacts from the PAMA Act while expanding its market presence and integration efforts.
Nearly 1 in 3 people with Lyme antibodies had others too. A parasite found alongside Lyme needs different treatment.
A Quest Diagnostics study published in JAMA Network Open found that nearly one in three U.S. patients with Lyme disease antibodies also had antibodies to at least one other tick-borne pathogen. The study, which analyzed over 193,000 test results, highlighted that co-seropositivity was highest in the Northeast, with Babesia microti being the most common co-detected pathogen. This finding emphasizes the importance of comprehensive testing for tick-borne diseases, as co-infections like Babesiosis require different treatments than Lyme disease and can be missed with single-pathogen testing.
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services
Shares of Quest Diagnostics (DGX) and Labcorp (LH) declined in premarket trading after Medicare indicated impending cuts to payment rates for laboratory services. This news suggests potential financial pressures for these major diagnostic companies. The full article is premium content, requiring a subscription to read.
Cerenome Names Samantha Fowlkes to Lead CNSide Commercial Sales
Cerenome Inc. (Nasdaq: CNSY) has appointed Samantha Fowlkes as vice president and head of commercial sales for its CNSide Diagnostics division. Fowlkes will lead the expansion and adoption of the company’s cerebrospinal fluid-based testing platform, CNSide, leveraging her two decades of experience in oncology diagnostics and precision medicine. Her role is crucial for strengthening relationships across oncology and pathology, increasing the platform's use, and building the commercial infrastructure for growth.
Quest Diagnostics Has Carved Out a Narrow Moat on Its Attractive Cost Structure
Quest Diagnostics, a leading provider of diagnostic testing in the US, benefits from a narrow economic moat due to its scale-driven cost advantage and extensive network of patient service centers. The company is well-positioned to capitalize on industry trends like increased diagnostic testing and personalized therapies. Additionally, Quest is experiencing a temporary relief from Medicare pricing pressures, contributing to an optimistic outlook for its performance.
GRAIL at Morgan Stanley conference: FDA, coverage seen as key By Investing.com
GRAIL presented at Morgan Stanley's 24th Annual Global Healthcare Conference, emphasizing that its Galleri blood test is nearing a broader commercial phase contingent on clinical evidence, FDA approval, and payer coverage. The company highlighted strong test metrics, increased volumes, and ongoing improvements, stressing that FDA approval is a critical step to reduce competitive noise and accelerate payer discussions for wider adoption. GRAIL also discussed its international expansion plans and the importance of health system integration and physician experience in driving routine use of the test.
Quanterix appoints Yuri Fesko as chief medical officer
Quanterix Corporation (NASDAQ:QTRX) has appointed Dr. Yuri Fesko as its new Chief Medical Officer. Dr. Fesko will lead medical and clinical initiatives across various departments as the company prepares to launch its Lucent AD Complete five biomarker test for Alzheimer's Disease. He brings extensive experience in precision medicine and advanced diagnostics from his previous role as CMO at Quest Diagnostics.
New 2027 CPT codes released as AMA faces mounting criticism
The American Medical Association has released its 2027 CPT code set, which includes new AI-related service codes and a revised maternity care framework. This release comes amidst increasing criticism and lawsuits challenging the AMA's copyright over the widely used medical coding system, with critics arguing for public domain access and questioning the AMA's financial interests in the system. The AMA, however, defends the CPT codes as essential for incorporating new medical services and ensuring health data interoperability.
